Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

NCT05660954 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Differentiated Thyroid Cancer

Interventions

DRUG: Cabozantinib

Sponsor

Grupo Espanol de Tumores Neuroendocrinos

Collaborators

[object Object]
[object Object]